gimatecan
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 11, 2019 (NCT04029909)
Timeline
Indications
Mechanism of action
- DNADEGRADER
DNA degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04846842 | Phase 2 | Jul 1, 2021 | Chongqing Tumor Hospital, Lee's Pharmaceutical |
| NCT04571489 | Phase 2 | Dec 1, 2020 | Jiao Tong University, Lee's Pharmaceutical |
| NCT04501029 | Phase 2 | Oct 1, 2020 | Lee's Pharmaceutical, People's Liberation Army of China |
| NCT04029909 | Phase 1 | Jul 11, 2019 | Beijing Tumor Hospital, Lee's Pharmaceutical |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lee's Pharmaceutical | For profit | 4 | 4 | 2 | 2019 |
| Beijing Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Chongqing Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1